First Time Loading...

Fate Therapeutics Inc
NASDAQ:FATE

Watchlist Manager
Fate Therapeutics Inc Logo
Fate Therapeutics Inc
NASDAQ:FATE
Watchlist
Price: 3.8 USD -1.81% Market Closed
Updated: Apr 29, 2024

Fate Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fate Therapeutics Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Fate Therapeutics Inc
NASDAQ:FATE
Revenue
$63.5m
CAGR 3-Years
26%
CAGR 5-Years
68%
CAGR 10-Years
52%
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.1B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

See Also

What is Fate Therapeutics Inc's Revenue?
Revenue
63.5m USD

Based on the financial report for Dec 31, 2023, Fate Therapeutics Inc's Revenue amounts to 63.5m USD.

What is Fate Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
52%

Over the last year, the Revenue growth was -34%. The average annual Revenue growth rates for Fate Therapeutics Inc have been 26% over the past three years , 68% over the past five years , and 52% over the past ten years .